Arcellx Inc.
Arcellx, Inc. Announces Change in Independent Registered Public Accounting Firm
Summary
On March 8, 2024, Arcellx, Inc. announced the dismissal of Ernst & Young LLP (EY) as its independent registered public accounting firm and the engagement of PricewaterhouseCoopers LLP (PwC) as its new independent registered public accounting firm for the fiscal year ending December 31, 2024. The dismissal of EY was not related to any disagreements on accounting principles, financial statement disclosure, or auditing scope or procedure. The Company's reports for the fiscal years ended December 31, 2023 and 2022, did not contain any adverse opinions or disclaimers, and there were no reportable events except for a previously reported material weakness in internal control over financial reporting which was remediated as of December 31, 2022. PwC's engagement is subject to their customary client acceptance procedures and the execution of an engagement letter, which was executed on March 13, 2024.
Profitelligence Alerts
Get alerts for ACLX
Be first to know when Arcellx Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Arcellx Inc.
Arcellx Inc. is a biopharmaceutical company specializing in the development of innovative cell therapies for the treatment of cancer and other debilitating diseases. The company's primary goal is to harness the power of the immune system through its proprietary D-Domain technology platform, which is designed to improve the efficacy and safety of cell-based treatments. Arcellx focuses on targeting malignant cells with precision, thereby enhancing therapeutic outcomes and minimizing adverse effects. Operating within the highly complex and rapidly evolving biotechnology sector, Arcellx significantly contributes to advancements in life sciences and medical treatments. Given its commitment to pioneering scientific discoveries, the company represents a significant player in the push towards personalized medicine and novel cancer therapies. Through collaboration with academic institutions and strategic partnerships, Arcellx endeavors to accelerate the development and commercialization of its pipeline products, aiming to bring life-changing treatments to patients worldwide. Its research-intensive approach and focus on addressing unmet medical needs position Arcellx as an impactful entity in the biopharmaceutical landscape.
Official SEC Documents
Advertisement